Neoadjuvant Therapy of Cervical Carcinoma with the Angiogenesis Inhibitor Bevacizumab: a Single-Centre Analysis

Abstract

Introduction Cervical cancer is the fourth most frequent cancer in women worldwide. Addition of the VEGF antibody bevacizumab in combination with platinum-containing chemotherapy achieved an improvement in overall survival in advanced cervical cancer. To date there are no data on neoadjuvant use of bevacizumab. We therefore studied the benefit of neoadjuvant combined therapy with bevacizumab in a group of cervical cancer patients.

Patients and Methods This retrospective cohort study analysed 14 patients with cervical cancer FIGO stages 1b1 to IV who received neoadjuvant platinum-containing chemotherapy in combination with bevacizumab. The comparative cohort consisted of 16 patients who were treated with neoadjuvant platinum-containing chemotherapy alone. The response rates were determined by means of preoperative clinical examination, diagnostic imaging (RECIST), changes in tumour markers (SCC) and by histopathology.

Results A clinical response was found in 93.8% (n = 15) of patients after bevacizumab-free therapy and in 100% (n = 14) of the patients who were treated with bevacizumab in addition. Combined therapy with bevacizumab led to a higher rate of clinical complete remission (42.9 vs. 12.5%; p = 0.072) and significantly improved the reduction in tumour size (Δ longest diameter: 3.7 vs. 2.5 cm; p = 0.025). Downgrading was observed in 100% of all patients treated with bevacizumab compared with 75% in the control arm. The rate of pathological complete remission (pCR) was not altered significantly (28.6% [n = 4] vs. 37.5% [n = 6]; p = 0.460).

Discussion Overall, combined therapy with bevacizumab led to a better clinical response. Operability was therefore improved more often. Because of the small patient cohort, larger prospective studies are necessary to validate the effect of neoadjuvant combined therapy with bevacizumab.

Key words

bevacizumab - VEGF antibody - cervical cancer - neoadjuvant chemotherapy

^* contributed equally

• References/Literatur

• 1 Ferlay J, Soerjomataram I, Dikshit R. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012. Int J Cancer 2015; 136: E359-E386
• 2 Robert-Koch Institut. Krebs in Deutschland. Zentrum für Krebsregisterdaten des Robert-Koch-Institut. 3.16 Gebärmutterhals. 2016 Online: https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2017/kid_2017_c53_gebaermutterhals.pdf;jsessionid=1871430DA6305EC0F3DCFEC3A8675578.2_cid290?__blob=publicationFile last access: 05.06.2018
• 3 Beckmann M, Mallmann P. S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom Version 1. – September 2014. Online: https://www.awmf.org/uploads/tx_szleitlinien/032-033OLl_S3_Zervixkarzinom_2014-10.pdf last access: 05.06.2018
• 4 Rydzewska L, Tierney J, Vale CL. et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2010; (01) CD007406
• 5 Kim HS, Sardi JE, Katsumata N. et al. Efficacy of neoadjuvant chemotherapy in patients with FIGO stage IB1 to IIA cervical cancer: an international collaborative meta-analysis. Eur J Surg Oncol 2013; 39: 115-124
• 6 Jackson MW, Rusthoven CG, Fisher CM. et al. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther 2014; 7: 751-759
• 7 Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl. 03) 4-10
• 8 Vici P, Mariani L, Pizzuti L. et al. Emerging biological treatments for uterine cervical carcinoma. J Cancer 2014; 5: 86-97
• 9 Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012; (03) a006486 doi:10.1101/cshperspect.a006486
• 10 Beckmann M. Bevacicumab beim fortgeschrittenen Zervixkarzinom: erste zielgerichtete Therapie mit signifikantem Überlebensvorteil bei fortgeschrittenem Zervixkarzinom. Thieme Drug Report. Stuttgart: Thieme; 2015
• 11 Yuan F, Chen Y, Dellian M. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996; 93: 14765-14770
• 12 Monk BJ, Sill MW, Burger RA. et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009; 27: 1069-1074
• 13 Tewari KS, Sill MW, Long HJ. et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-743
• 14 Tewari K, Sill M, Penson R. et al. LBA26 ESMO 2014: Final Overall Survival Analysis of the Phase III Randomised Trial of Chemotherapy With and Without Bevacizumab for Advanced Cervical Cancer: A NRG Oncology-Gynecologic Oncology Group Study. Ann Oncol 2014; DOI: 10.1093/annonc/mdu438.27.
• 15 Schefter T, Winter K, Kwon JS. et al. RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys 2014; 88: 101-105
• 16 Therasse P, Arbuck SG, Eisenhauer EA. et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
• 17 Eisenhauer EA, Therasse P, Bogaerts J. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
• 18 Barnard GA. A New Test for 2 × 2 Tables. Nature 1945; 156: 783-784
• 19 Beskow C, Agren-Cronqvist AK, Granath F. et al. Pathologic complete remission after preoperative intracavitary radiotherapy of cervical cancer stage Ib and IIa is a strong prognostic factor for long-term survival: analysis of the Radiumhemmet data 1989-1991. Int J Gynecol Cancer 2002; 12: 158-170
• 20 Kong S, Huang K, Zeng C. et al. The association between short-term response and long-term survival for cervical cancer patients undergoing neoadjuvant chemotherapy: a system review and meta-analysis. Sci Rep 2018; DOI: 10.1038/s41598-018-19948-0.
• 21 Folkman J, Watson K, Ingber D. et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58-61
• 22 Tokumo K, Kodama J, Seki N. et al. Different angiogenic pathways in human cervical cancers. Gynecol Oncol 1998; 68: 38-44
• 23 Cooper RA, Wilks DP, Logue JP. et al. High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res 1998; 4: 2795-2800
• 24 Saijo Y, Furumoto H, Yoshida K. et al. Clinical Significance of Vascular Endothelial Growth Factor Expression and Microvessel Density in Invasive Cervical Cancer. J Med Invest 2015; 62: 154-160
• 25 Randall LM, Monk BJ, Darcy KM. et al. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol 2009; 112: 583-589
• 26 Lee KC, Kim HJ, Sung K. et al. The Predictive Value of Tumor Size, Volume, and Markers During Radiation Therapy in Patients With Cervical Cancer. Int J Gynecol Cancer 2017; 27: 123-130
• 27 Fachinformation Avastin^®. Juni 2017.